A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity

Por Polk, Anne, Vistisen, Kirsten, Vaage-Nilsen, Merete, Nielsen, Dorte L
Publicado em 2014

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

Por Kümler, Iben, Knoop, Ann S, Jessing, Christina A R, Ejlertsen, Bent, Nielsen, Dorte L
Publicado no ESMO Open (2016)

Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period

Por Abu Hassan, Suher O, Nielsen, Dorte L, Tuxen, Malgorzata K, Petersen, Per H, Sölétormos, György
Publicado no Future Sci OA (2017)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

Por Jørgensen, Charlotte LT, Ejlertsen, Bent, Bjerre, Karsten D, Balslev, Eva, Nielsen, Dorte L, Nielsen, Kirsten V
Publicado em 2013

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

Por Jørgensen, Charlotte Levin Tykjær, Bjerre, Christina, Ejlertsen, Bent, Bjerre, Karsten D, Balslev, Eva, Bartels, Annette, Brünner, Nils, Nielsen, Dorte L
Publicado em 2014

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan

Por Schou, Jakob V., Rossi, Simona, Jensen, Benny V., Nielsen, Dorte L., Pfeiffer, Per, Høgdall, Estrid, Yilmaz, Mette, Tejpar, Sabine, Delorenzi, Mauro, Kruhøffer, Mogens, Johansen, Julia S.
Publicado em 2014